The Centers for Medicare & Medicaid Services July 16 released draft guidance for the 2028 cycle of negotiations under the Medicare Drug Price Negotiation program. Policies on incorporating drugs payable under Medicare Part B or covered under Part D are included in the guidance. It also describes procedures that may apply to drug manufacturers, Part D plan sponsors, Medicare Advantage organizations, pharmacies, mail order services and other Part D drug-dispensing entities, as well as hospitals, physicians and other providers that furnish or administer drugs payable under Part B. CMS is accepting comments on the draft guidance until Sept. 18. 

Headline
The American Medical Association Nov. 17 released its latest annual report on health insurance competition, which found that 95% of commercial markets were…
Headline
The Medicare Part A deductible for inpatient hospital services will increase by $40 in calendar year 2026 to $1,776, the Centers for Medicare & Medicaid…
Headline
The Centers for Medicare & Medicaid Services Nov. 16 issued a proposed rule on program integrity oversight in Medicare, Medicaid, the Children’s Health…
Headline
The Centers for Medicare & Medicaid Services Nov. 5 published a final rule to codify the Medicare Drug Price Negotiation Program beginning in 2029. The…
Headline
The estimated average monthly premium for Medicare Part D stand-alone prescription drug plans is $51 for 2027, a 50% increase from $34 in 2026, for enrollees…
Headline
The Department of Labor Oct. 29 finalized a rule designed to improve transparency of fees collected by pharmacy benefit managers. The rule requires PBMs to…